INMD Stock Risk & Deep Value Analysis
Inmode Ltd
DVR Score
out of 10
What You Need to Know About INMD Stock
We analyzed Inmode Ltd using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran INMD through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Moderate. Here's what we found.
How Risky Is INMD Stock?
Overall Risk
Moderate
Financial Risk
Low
Market Risk
Medium
Competitive Risk
Medium
Execution Risk
Medium
Regulatory Risk
Medium
What Are the Red Flags for INMD?
- ⚠
Slower-than-expected recovery in consumer discretionary spending for aesthetics
- ⚠
New, highly competitive technology emerging from rivals
- ⚠
Negative regulatory changes impacting medical device sales or approvals
- ⚠
Increased price pressure on devices or consumables
Unlock INMD Red Flags & Risk Warnings
Create a free account to see the full analysis
Is INMD Stock Undervalued?
Unlock the full AI analysis for INMD
Get the complete DVR score, risk analysis, and more
Does INMD Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Stable
Moat Sources
3 Identified
InMode's moat is largely protected by its proprietary radiofrequency (RF) technology and a robust patent portfolio. The strong brand recognition of products like Morpheus8 creates significant customer loyalty and a network effect among clinicians. Switching costs arise from the training required to operate InMode platforms and the continued purchase of proprietary consumables. However, the medical aesthetics market is dynamic, requiring continuous innovation to maintain this edge.
Moat Erosion Risks
- •Emergence of a genuinely disruptive, non-RF based aesthetic technology
- •Patent expirations or successful challenges to IP
- •Aggressive pricing strategies by competitors leading to margin erosion
INMD Competitive Moat Analysis
Sign up to see competitive advantages
What Could Drive INMD Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings (Estimated early-May 2026)
- •Launch of new handpieces or software upgrades for existing platforms
- •Positive commentary on recovery of elective procedure demand
Medium-Term (6-18 months)
- •Expansion into new international markets (e.g., Asia Pacific, Latin America)
- •Major regulatory approvals for new platforms or indications
- •Strategic partnerships to expand clinic adoption or training programs
Long-Term (18+ months)
- •Further penetration into the broader medical aesthetics market, potentially through M&A
- •Disruption of traditional surgical procedures with less invasive alternatives
- •Establishment of InMode as the dominant player in RF-based aesthetics
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for INMD?
- ✓
Acceleration in year-over-year and sequential revenue growth rates
- ✓
Positive commentary and strong guidance from management regarding market recovery
- ✓
Continued high adoption rates of new product launches and handpieces
Bull Case Analysis
See what could go right with Premium
Compare INMD to Similar Stocks
See how Inmode Ltd stacks up against related companies in our head-to-head analysis.
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for INMD (Inmode Ltd) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.


